Piccinin G L, Finali G, Piccirilli M
Clinic of Neurology, Perugia University, Italy.
Clin Neuropharmacol. 1990 Apr;13(2):147-63. doi: 10.1097/00002826-199004000-00004.
The monoaminergic neurotransmission defect seen in dementia of the Alzheimer type (DAT) is linked to a known increased activity of type B cerebral monoamine oxidases (MAO-Bs). The use of drugs that are able to block this abnormal activity could therefore be useful in the treatment of some cognitive deficits that characterize DAT. Twenty patients with a clinical diagnosis of DAT and with a slight-moderate mental deterioration were treated with 10 mg/day of L-deprenyl, a selective MAO-B inhibitor, according to a double-blind crossover design vs. placebo. Initial treatment (drug or placebo) was randomly assigned. The patients' cognitive functions were evaluated at baseline and then after 3 and 6 months of treatment with drug or placebo. The patients crossed over treatment after 3 months, without a washout interval. The results of the study show the higher and statistically significant effects of L-deprenyl on memory and attention that seem to be due to an improved function of the monoaminergic systems involved in the process of neuronal degeneration.
在阿尔茨海默型痴呆（DAT）中所见的单胺能神经传递缺陷与已知的B型脑单胺氧化酶（MAO-B）活性增加有关。因此，使用能够阻断这种异常活性的药物可能有助于治疗DAT所特有的一些认知缺陷。根据双盲交叉设计，对20例临床诊断为DAT且有轻度至中度精神衰退的患者，给予10毫克/天的L-司来吉兰（一种选择性MAO-B抑制剂）治疗，与安慰剂对照。初始治疗（药物或安慰剂）随机分配。在基线时以及使用药物或安慰剂治疗3个月和6个月后对患者的认知功能进行评估。患者在3个月后交叉治疗，无洗脱期。研究结果表明，L-司来吉兰对记忆和注意力有更高且具有统计学意义的影响，这似乎是由于参与神经元变性过程的单胺能系统功能改善所致。
